FDA clears Alpha Tau to advance REGAIN trial enrolment

Alpha Tau Medical has received clearance from the US FDA to proceed with enrolment of the final seven patients in its REGAIN trial for recurrent glioblastoma. The decision follows the FDA’s review of an interim safety report for the first three patients treated in the trial. The trial will evaluate the feasibility and safety of Alpha Tau’s Alpha DaRT therapy for patients with recurrent glioblastoma. Credit: H_Ko / Shutterstock.com. Alpha Tau Medical has received clearance from the US Food and Drug Administration (FDA) to proceed with enrolment of the final seven patients in its REGAIN trial for recurrent glioblastoma (GBM).…

Source: Medical Device Network